CCL19 is more potent than CCL21 in inducing chemotaxis of human dendritic cells (DC). This difference is attributed to 1) a stronger interaction of the basic C-terminal tail of CCL21 with acidic glycosaminoglycans (GAGs) in the environment and 2) an autoinhibitory function of this C-terminal tail. Moreover, different receptor docking modes and tissue expression patterns of CCL19 and CCL21 contribute to fine-tuned control of CCR7 signaling. Here, we investigate the effect of the tail of CCL21 on chemokine binding to GAGs and on CCR7 activation. We show that transfer of CCL21-tail to CCL19 (CCL19 CCL21-tail ) markedly increases binding of CCL19 to human dendritic cell surfaces, without impairing CCL19-induced intracellular calcium release or DC chemotaxis, although it causes reduced CCR7 internalization. The more potent chemotaxis induced by CCL19 and CCL19 CCL21-tail compared to CCL21 is not transferred to CCL21 by replacing its N-terminus with that of CCL19 (CCL21 CCL19-N-term ). Measurements of cAMP production in CHO cells uncover that CCL21-tail transfer (CCL19 CCL21-tail ) negatively affects CCL19 potency, whereas removal of CCL21-tail (CCL21 tailless ) increases signaling compared to full-length CCL21, indicating that the tail negatively affects signaling via cAMP. Similar to chemokine-driven calcium mobilization and chemotaxis, the potency of CCL21 in cAMP is not improved by transfer of the CCL19 N-terminus to CCL21 (CCL21 CCL19-N-term ). Together these results indicate that ligands containing CCL21 core and C-terminal tail (CCL21 and CCL21 CCL19-N-term ) are most restricted in their cAMP signaling; a phenotype attributed to a stronger GAG binding of CCL21 and defined structural differences between CCL19 and CCL21.
INTRODUCTION
The chemokine receptor CCR7 plays an essential role guiding both innate and acquired immune responses. During immune cell activation, CCR7 controls CCL21 directed migration of both matured dendritic cells (DC, professional antigen-presenting cells) and naïve T cells to the lymph nodes (LN), 1 but also coordinates the subsequent encountering of antigen-presenting DCs with naïve T cells in the LN. Thus LN stromal Abbreviations: 3D, three-dimensional; BBXB, basic basic X basic; BRET, bioluminescence resonance energy transfer; CHO, Chinese hamster ovary; CI, chemotactic index; DC, dendritic cell; GAG, glycosaminoglycan; GRK, G protein-coupled receptor kinase; HEK, human embryonic kidney; HS, heparan sulfate; IP 3 , inositol triphosphate; LN, lymph node; moDC, monocyte derived DC; NMR, nuclear magnetic resonance; RP, reverse phase; RT, room temperature cell secreted CCL19 and CCL21 are both important for orchestrating initial contacts between DCs and naïve T cells in LN T-cell zones as well as for stimulating chemokinesis of T-cells within LN. 2, 3 On the other hand, autocrine CCL19 secretion by DCs may play a role in short-lived CCL19 guiding of the DC:T cell scanning process, [4] [5] [6] with the shorttime span of CCL19 signaling compared to CCL21, making it ideal for recent studies have provided evidence that these ligands are also functionally distinct signaling molecules. CCL19 seems to be more potent in inducing -arrestin 2 recruitment and CCR7 internalization in various established cell lines, and, importantly, a more potent chemotactic cue in guiding DC chemotaxis compared to CCL21. [14] [15] [16] [17] [18] In contrast, CCL21 seems to be as strong as or stronger than CCL19 in inducing intracellular calcium release and ERK activation in DCs. 14, 19, 20 Thus CCL19 and CCL21 give rise to biased CCR7 signaling 9 ; a phenomenon not only observed in CCR7, but also among other chemokine receptors. [21] [22] [23] Chemokines are named according to the position of two conserved cysteines and are divided into 2 major groups, the CC and the CXC chemokines. CX 3 CL1 separates itself from the rest by the conserved cysteines being separated by 3 amino acids. XCL1 and XCL2 differ by lacking one of the two conserved N-terminal cysteines and they therefore only form 1 cysteine bridge, in contrast to the rest of the chemokines that form 2 disulphide bridges with 2 conserved cysteines located in the core domains of the chemokines. CCL21 has 2 additional cysteines in its C-terminus (thus 6 in total) and forms a third cysteine bridge. 24 Chemokine induced receptor activation relies on docking of the ligand N-terminus deep into the receptor binding pocket. 25, 26 Since CCL19 and CCL21 have different N-termini, they are expected to interact with and thus activate CCR7 in different ways. Earlier studies have presented data on the interaction of CCL19 and CCL21 with CCR7. 14, 27, 28 Altogether these studies support different docking modes of the two chemokines, with specific amino acid residues in the receptor being differentially important for activation by one ligand without affecting activation by the other. Thus amino acids in the top of transmembrane segment (TM)3 and TM4, in the area of the major binding pocket (encircled by TM3-7) are exclusively important for CCL21 induced CCR7 activation. 14 Recent modeling of CCL19 and CCL21 interactions with CCR7 suggests that CCL19 also makes ligand specific contacts with CCR7. 28 Furthermore, CCL19 and CCL21 only display 32% sequence identity and differ in length with CCL21 encoding a 37 amino acid long C-terminal tail extension that is lacking in CCL19, giving rise to significant differences in GAG affinity. [29] [30] [31] We have previously shown that CCL21 is captured on the surface of human monocyte derived DCs (moDCs) to a much higher extent than CCL19, a characteristic that is dependent on the basic C-terminal tail of CCL21. This extensive GAG binding is hypothesized to disturb both gradient sensing in three-dimensional (3D) chemotaxis and the immediate availability of the ligand for receptor interaction and signaling. 14 Finally, as described by Kiermaier et al., the tail of CCL21 seems to further control the chemokine activity, keeping it in an autoinhibited form, potentially through the tail folding back on the core domain, to be unlocked only upon binding to polysialic acid residues on CCR7, that is therefore of importance for CCL21 induced CCR7 activity in DCs where the polysialylation process is known to occur. 32 Regulation of CCL21 activity through regulation of GAG affinity and relief of CCL21 intramolecular tail autoinhibition are highly relevant physiological events, as both DC-released proteases and plasmin have been shown to cleave the tail of CCL21 to generate CCL21 tailless in vitro and in vivo. 33, 34 The direct contribution of the CCL21-tail to ligand-specific cell surface binding and receptor activation profile has not been investigated before, but is an important aspect in understanding the differential activation modes of CCL19 and CCL21, which will allow future interference with ligand subsets.
We therefore set out to determine the effect of CCL21-tail cell surface binding, on chemokine induced 3D chemotaxis and CCR7-mediated signal transduction, employing various chimeric CCR7 binding chemokines together with endogenous CCL19, CCL21 and CCL21 tailless to investigate the consequence of presence versus absence of a basic tail originating from CCL21. Chimeric ligand versions include CCL19 fused to the C-terminus of CCL21 (CCL19 CCL21-tail ) and a CCL21 version where the first 16 amino acids have been substituted by CCL19 specific residues (CCL21 CCL19-N-term ).
The latter chimera was created to determine whether the N-terminus of CCL19 can potentiate the otherwise weaker CCL21-induced signaling through alteration of CCR7 docking. with an unfolded protein. 35 Additionally, 15 N-1 H heteronuclear single quantum coherence spectra (HSQC) of uniformly 15 N/ 13 C labeled CCL19 CCL21-tail , as seen in Supplementary Fig. S2 , indicate this chimera is folded and that there are significant similarities between the corresponding CCL19 and CCL21 regions of this chimera and HSQC spectra of either CCL19 36 or residues corresponding to the tail of CCL21. 24 Protein NMR data was collected at the Medical College of Wisconsin's NMR facility as previously described. 35 
MATERIALS AND METHODS

Materials
DCs preparation
DCs were prepared from human PBMCs isolated from buffy coats by centrifugation on a Lymphoprep gradient. Briefly monocytes were isolated by plastic adherence of PBMC. Adhered monocytes were subsequently cultured and differentiated into immature DCs by incubation with IL-4 (250 U/mL) and GM-CSF (1000 U/mL) for 6 d, followed by activation into mature DCs by incubation with IL-6 (1000 U/mL), IL-1 (1000 U/mL),TNF-(1000 U/mL), and PGE2 (1 g/mL) for an additional 2 d in the same medium.
Cell culturing
Human DCs were grown in X-vivo 15 medium with 2% human AB serum and Glutamine. CHO-K1 cells were grown in RPMI with 10%FBS and penicillin/streptomycin. All cells were split routinely by dislodging in trypsin. All cells were kept in a humidified incubator at 37 • C, 5% CO 2 . For stable cell-lines the passage number did not exceed 40.
3D chemotaxis
Chemotaxis assays were conducted as previously described. 14 should have a CI close to zero, meaning that the cells move randomly in all directions to the same degree (meaning no overall movement in any direction). Theoretically, the maximal CI would be 1, meaning that every displacement of the cell is in the direction of the source (this is not observed in praxis).
Ligand DC surface staining
Thawed DCs were left to acclimatize in X-vivo 15 medium with 2% 
Flow-cytometry determination of ligand induced CCR7 internalization
DCs were stimulated for 30 min with medium or 1, 10, or 100 nM of CCL19, CCL21, or CCL19 CCL21-tail chimera at 37 • C and remaining CCR7 surface expression was determined (mean fluorescence intensity) by flow cytometry as described previously. 37 From all experiments the percentage of remaining CCR7 surface expression was calculated after chemokine-mediated receptor internalization in relation to CCR7 surface expression of cells incubated with medium alone. As control, cells were incubated for 30 min with 100 nM CCL19, CCL21, or CCL19 CCL21-tail at 4 • C to show that chemokine binding to CCR7 does not affect binding of the CCR7 specific Ab used to determine receptor internalization.
Calcium signaling
DCs were seeded in a poly-D-lysine coated white 96-well iso plate 
Bioluminescence resonance energy transfer (BRET) cAMP assay
CHO cells were seeded in a 6-well plate, 500,000 cells/well, and transiently co-transfected with vectors encoding the WT human CCR7 and Camyel sensor 38 in a 1:5 ratio using Lipofectamine 2000 (6 g/well).
The following day cells were resuspended in PBS with glucose and seeded in 96-well black/white iso plate (∼25,000 cells/well). Coelenterazine (camyel bioluminescence substrate) was added to a final con- 
Statistical analysis
Error bars are indicated as SEM. Statistical analysis performed are ttest and P-values < 0.01 indicated by ** and P values < 0.05 indicated by *. Non-significant differences are indicated by NS.
RESULTS
CCL21-tail transfer to CCL19 (CCL19 CCL21-tail ) increases surface binding to dendritic cells
It has previously been shown that removal of the extended basic C-terminal tail of CCL21 prevents the otherwise strong binding of CCL21 to the DC cell surface. 14 The CCL21-tail harbors 2 basic BBXB domains that convey affinity for acidic GAGs in the extracellular environment and on the cell membrane. To access the role of the tail in cell-surface binding, we used a chimeric version of CCL19, CCL19 CCL21-tail , containing the C-terminal tail (amino acids 78-111) of CCL21 (Fig. 1A) . Human moDCs were incubated on ice with either CCL19 or CCL19 CCL21-tail and the amount of ligand binding to cell surfaces over a fixed time period was subsequently determined via detection with fluorescently labeled antibodies. In contrast to CCL19 (Fig. 1A) , CCL19 CCL21-tail binds profoundly to the surface of human mature moDCs (Fig. 1B) . We used a commercially available Ab raised against CCL19 to detect both ligands. The Ab recognized both wild type CCL19 and CCL19 CCL21-tail as evaluated by ELISA (Fig. 1C) .
F I G U R E 1
Introducing the basic C-terminal tail of CCL21 onto CCL19 affects its GAG binding ability and surface interaction with DCs. Introducing the tail of CCL21 onto CCL19 causes its distinct binding to the surface of human mature moDCs (B) to a much higher extent than wild type CCL19 (A). The Ab used detects CCL19 CCL21-tail to the same degree as it detects CCL19 as estimated via ELISA on adsorbed ligands (C). Overview of wild type and chimeric CCR7 ligands used in this study (D), with cysteines bridges indicated with lines between the connected cysteines, and secondary structures above with beta-sheets shown as arrows and the alpha-helix as a banner. CCL21 tailless lacks 2 cysteines in the C-terminus compared to CCL21 and thus only forms 2 cysteine bridges. (Ligand surface staining's ( Fig. 1A and B) and ELISA data (Fig. 1 C) represent data from three separate experiments (n = 3)) Since antigen detection in ELISA is different from antigen detection in immune histochemistry (IHC), this is a rough estimate of how well the Ab detects CCL19 CCL21-tail compared to CCL19. The different wild type and chimeric chemokine versions tested throughout this study are depicted in a schematic illustration in Fig. 1D. 
CCL21-tail transfer to CCL19 (CCL19 CCL21-tail ) does not lower the chemotactic potency of CCL19 in DCs
As described before, CCL21 is a less potent chemotactic signal compared to CCL19 for human and murine DCs. 14, 20 To investigate whether the actual capture of CCL21-tail containing ligands on cell surface GAGs can be linked to a low chemotaxis inducing potency in DCs, we investigated whether the CCL21-tail transferred to CCL19 affected its chemotactic potential. Whereas CCL21 is less potent than CCL19, CCL19 CCL21-tail is as potent as CCL19 in inducing chemotaxis in 3D, both in collagen I gels ( Fig. 2A) and in more complex Matrigels (Fig. 2B) . This indicates that chemokine cell surface binding is not a determining factor for chemotactic potency in vitro. Spiderweb diagrams of DC chemotaxis toward 10 nM of CCL21 (Fig. 2C) , CCL19 CCL21-tail (Fig. 2D) , and CCL19 ( Movie 1-3 ).
CCL21-tail transfer to CCL19 (CCL19 CCL21-tail ) affects potency and efficacy of CCR7 internalization in DCs
CCL19 and CCL21 binding to CCR7 leads to recruitment of different GRKs that differentially affect -arrestin recruitment and subsequent CCR7 internalization, with CCL21 inducing considerable less CCR7 internalization compared to CCL19. 14, 15, 17 Here, we investigate if the increased surface binding of CCL19 CCL21-tail compared to CCL19 results in a change in CCR7 internalization pattern. For all chemokines we observed endocytosis in a concentration-dependent manner and experiments at 4 • C using 100 nM of chemokine showed that chemokine binding to the receptor does not prevent Ab binding (Fig. 3) . As expected, CCR7 was readily endocytosed after CCL19 stimulation. Stimulation with as little as 1 nM CCL19 already let to the internalization of about 30% of CCR7 whereas at 10 and 100 nM CCL19 about 50% of CCR7 was internalized (Fig. 3A) . Compared to CCL19, CCL19 CCL21-tail is less potent, especially at low concentrations, in inducing CCR7 endocytosis. Thus upon stimulation with 1 nM of CCL19 CCL21-tail only 20% of CCR7 was internalized and a maximum of 40% CCR7 endocytosis was reached for 100 nM CCL19 CCL21-tail (Fig. 3) . For CCL21, at 1 nM only 10% of CCR7 was internalized and at 100 nM only 25% of CCR7 was endocytosed. Hence, CCL19 CCL21-tail is more potent than CCL21, but not as potent as CCL19 in inducing CCR7 endocytosis (Fig. 3A) indicating that chemokine binding to cell surface GAGs at least partially interferes with ligand induced receptor internalization.
CCL21-tail transfer to CCL19 (CCL19 CCL21-tail ) does not affect CCL19-induced signaling via changes in intracellular calcium release in DCs
The fact that CCL19 CCL21-tail behaves like CCL21 with regard to DC surface binding, but like CCL19 with regard to chemotaxis and intermediate in receptor internalization spurred us to investigate if signaling via downstream pathways was influenced by the transfer of CCL21-tail to CCL19. Thus, we measured intracellular calcium release in response to CCL21, CCL19, and CCL19 in human moDCs and found that CCL19 CCL21-tail resembles neither CCL19 nor CCL21 with regard to inducing intracellular calcium mobilization (Fig. 4A-D) . Overall, CCL21 induces intracellular calcium release with both higher potency and higher efficacy compared to CCL19, with CCL19 CCL21-tail reaching a level somewhere in between (Fig. 4D) . These data show that the higher potency of CCL19 and CCL19 CCL21-tail in terms of controlling chemotaxis does not correlate with the potency of these chemokines in mobilization of intracellular calcium.
CCL19 N-terminus transfer to CCL21 (CCL21 CCL19-N-term ) does not rescue the low chemotactic potency of CCL21 in DCs
We wondered if the higher potency of CCL19 and CCL19 CCL21-tail in chemotaxis, compared to CCL21, was conveyed by the N-terminus of CCL19 given the presumed different receptor docking mode of the N-termini of these ligands, 14 or whether the differences in activation profiles reside in the overall difference in the chemokine core structures. To test this, we employed another chimeric chemokine in which the first 16 N-terminal amino acids of CCL21 were exchanged with the equivalent part of CCL19, named CCL21 CCL19-N-term (Fig. 5A ). This chimera retained the poor potency of CCL21 in inducing chemotaxis of human DCs (Fig. 5B ).
CCL19 N-terminus negatively affects potency of CCL21 signaling via intracellular calcium release
Since CCL21 CCL19-N-term resembled CCL21 with regard to chemotaxis inducing potential, we next tested the ability of this chimera to signal via changes in intracellular calcium. As previously shown (Fig. 4) CCL21, CCL19 CCL21-tail , and CCL19 are all potent in inducing intracellular calcium release, although CCL21 and CCL19 CCL21-tail seem to be more efficient than CCL19 (Fig. 6C and D) . CCL21 CCL19-N-term on the other hand displays a significantly reduced activity through this F I G U R E 4 Introducing the basic C-terminal tail of CCL21 onto CCL19 does not affect its ability to signal via calcium in human DCs. Both CCL19 and CCL21 signal efficiently via calcium in human DCs. CCL19 CCL21-tail retains this activity. Thus CCL21 tail does not significantly affect intracellular calcium release, all ligands are biologically active. The three ligands elicit similar responses at 1 nM, 10 nM, and 100 nM concentrations (A-C). CCL21 open squares, CCL19 closed black squares and CCL19 CCL21-tail closed black triangles (n = 6-10). Dose response curves based on the maximal response elicited by the different chemokine concentrations (D), reveal that CCL21 is both more potent and more efficient than CCL19 in eliciting intracellular calcium release.
F I G U R E 5
The higher potency of CCL19 CCL21-tail compared to CCL21 cannot be transferred to CCL21 by CCL19 N-terminus. Overview of wild type and chimeric CCR7 ligands used in this assay (A). The CCL21 CCL19-N-term chimera, in which the first 16 amino acids of CCL21 have been replaced with the first 16 amino acids of CCL19, retains the low potency of CCL21 in chemotaxis (B)(n = 4) pathway compared to both CCL21 and CCL19 (Fig. 6A,   C, and D) . Interestingly, CCL21 tailless is even less potent than CCL21 CCL19-N-term (Fig. 6A, B, C, and D) .
CCL21-tail negatively affects signaling via changes in cAMP and CCL19 N-terminus is not able to rescue the poor potency of CCL21 derived ligands
Since the abilities of the tested chemokines to signal via calcium mobilization do not correlate with their chemotaxis inducing potential, we investigated whether G i -signaling resulting in reduced cAMP production could be related to ligand potency controlling chemotaxis.
We therefore tested the effect of CCL19, CCL19 CCL21-tail , CCL21, CCL21 CCL19-N-term , and CCL21 tailless for their ability to signal via cAMP.
We used a BRET-based assay to measure decrease in cAMP, following G i -mediated inhibition of forskolin-induced adenylate cyclase activity in transfectable CHO cells.
Our results show that transfer of CCL21-tail to CCL19 impairs its ability to signal via cAMP as CCL19 CCL21-tail displays a 15-fold decreased potency compared to CCL19 (EC 50 of 18.4 nM, log EC 50 ± SEM: −7.74 ± 0.2 vs. EC 50 of 1.14 nM, log EC 50 ± SEM: −8.94 ± 0.12) (Fig. 7) . On the other hand CCL19 CCL21-tail is still F I G U R E 6 CCL19 N-terminus negatively affects CCL21 induced signaling via calcium in human DCs, and tail removal reduces CCL21 potency even more. As previously shown CCL21, CCL19 CCL21-tail , and CCL19 are all potent in inducing intracellular calcium release (Fig. 6A-C) with CCL21 and CCL19 CCL21-tail displaying a significantly higher efficacy than CCL19 (P ≤ 0.01** at 100 nM). On the other hand CCL21 CCL19-N-term displays a significantly reduced activity through this pathway compared to both CCL21 and (P ≤ 0.01** at 10 and 100 nM) and CCL19 CCL21-tail (P ≤ 0.05* and P ≤ 0.01** at 10 and 100 nM, respectively). Interestingly, CCL21 tailless was even less potent than CCL21 CCL19-N-term (n = 3-5) F I G U R E 7 The inhibitory effect on signaling via cAMP is driven by the CCL21 tail and further enhanced by the CCL21 core domain. As with adding CCL21 tail to CCL19 (CCL19 CCL21-tail ) resulting in decreased signaling, removing the tail of CCL21 results in improved signaling properties (CCL21 tailless ) (Decrease in intracellular cAMP is reflected by an increase in BRET ratio) in CHO cells. CCL21 CCL19-N-term displays low potency in cAMP signaling like CCL21 (n = 3) more potent than CCL21 that displays a much lower potency (∼15-fold) in cAMP signaling (estimated EC 50 ∼260 nM, log EC 50 ± SEM: −6.57 ± 0.06) (Fig. 7) .
We next addressed whether removal of the tail from CCL21 would increase its potency. Indeed, CCL21 tailless was improved approximately 15-fold in its ability to signal via cAMP compared to CCL21 and CCL21 CCL19-N-term with a potency similar to CCL19 CCL21-tail (EC 50 of 12.5 nM, log EC 50 ± SEM: −7.9 ± 0.12) (Fig. 7) . This indicates that CCL21-tail alone negatively affects ligand induced signaling in this pathway.
Since both CCL21 and CCL21 CCL19-N-term display low potency in this assay, it seems that the tail together with CCL21 core domain has a negative influence on signaling via cAMP and that the ability to signal via this pathway may correlate with the chemotaxis inducing potency, where these ligands both display a similarly poor activity.
DISCUSSION
Signaling bias is well established in the chemokine system. 39 For CCR7, there are some discrepancies across studies with regard to relative potencies of CCL19 and CCL21 in signaling via G i (probably reflecting the use of different cells and assay systems), 14 but CCL19 has consistently been proven to be more potent in inducing CCR7 phosphorylation, -arrestin recruitment and internalization, in various established cell-lines and primary cells, 7, 14, [16] [17] [18] and has also been shown to be a more potent chemotactic signal for both murine and human DCs compared to CCL21. 14, 20 Based on our previous observations that CCL21 binds extensively to DC surfaces and is a poor chemotactic signal compared to CCL19, and that removal of the tail (CCL21 tailless ) diminish surface gluing and rescue chemotaxis, 14 we hypothesized that the low potency of CCL21 could be attributable to its extensive surface binding, disturbing external gradient sensing and immediate ligand availability. In the present work, we investigate the effect of ligand cell surface binding via CCL21-tail on 3D chemotaxis and signaling properties, by employing various chimeric CCR7 ligands to investigate the consequence of presence versus absence of the tail. Most experiments were carried out in human moDCs, except studies on signaling via cAMP which were performed in CHO cells, due to the need for transfection when using the camyel sensor system. 38 Strong GAG binding by CCL21 is a well-known phenomenon, 29, 30, 40 but the fact that it binds extensively to not only endothelial cells, but also to the surface of immune cells could potentially affect availability for receptor interaction, with different GAGs having different effects on receptor interaction and signaling. Interestingly, binding of CCL21 to chondroitin sulfate B has previously been shown to inhibit signaling via CCR7 whereas binding to heparan sulfate (HS) had no such inhibitory effect. 30 Here we show that transfer of the CCL21-tail to CCL19 (CCL19 CCL21-tail ) does not negatively affect CCL19's ability to induce chemotaxis in human DCs, despite the increased surface binding of this chimera to DC surfaces, ruling out that binding to the cell surface per se interferes with chemotaxis. Our finding is consistent with a study by Barmore et al. 31 that reveals increased heparin binding by the same chimera, CCL19 CCL21-tail compared to CCL19, which demonstrates that the basic C-terminal tail of CCL21 is enough to confer high GAG affinity. Interestingly, we show here, that CCR7 internalization driven by CCL19 CCL21-tail decreased compared to CCL19 but is not as low as for CCL21, indicating that high GAG affinity somehow has an effect on the ability of CCR7 to internalize. GAGs in the environment together with the core domain also affect CCL21-mediated CCR7 activation. Our data support that it is the CCL21-tail in combination with the CCL21 core domain that leaves CCL21 a less potent signaling molecule in these readouts compared to CCL19.
As summarized in Table 1 , all chemokines tested in this study are potent in at least one readout (calcium, cAMP, CCR7 endocytosis, or 3D chemotaxis), except for CCL21 CCL19-N-term , and thus, in general, we believe that the effects we describe herein are not based on changes in CCR7 affinity between the chemokines tested, although this cannot be ruled out for CCL21 CCL19-N-term .
In a study by Kiermaier et al. 32 it was shown that CCL21 signaling is impaired due to an autoinhibitory function of the tail, that is envisioned to fold back on the chemokine, creating a locked autoinhibited CCL21 form, which is unlocked upon binding to polysialic acid residues on CCR7, that is, therefore, of importance for CCL21 induced CCR7 activity. This group found both CCL21 and CCL19 CCL21-tail induced chemotaxis of murine DCs to be dependent on expression of polysialylation enzymes (including St8sia4) by the DCs. 32 NMR spectra suggest that there is a change in conformation between CCL21 and CCL21 tailless resulting from tail deletion suggesting that tail interactions with the core chemokine domain in CCL21 result in an autoinhibited state. 32 Whether this forced change in conformation is also occurring in CCL19 and therefore affects CCL19 CCL21-tail activity was not addressed in this study.
In the current study, we do not address the effect of polysialylation on relief of tail induced autoinhibition as such but our data indicate that differences in overall chemokine structure relay variances in signaling strength that are polysialylation independent, as we show that CCL21 is less potent than CCL19 CCL21-tail in inducing human DC migration, where polysialylation is expected to take place, and that it is also less potent than CCL19 CCL21-tail in cAMP signaling in CHO cells that do not perform polysialylation.
In summary, we show that enhanced CCL21 tail-mediated binding of chemokines to the DC cell surface does not itself disturb ligand potency in chemotaxis and calcium signaling, although it negatively affects CCR7 internalization and CCR7 induced G i mediated reduction in cAMP. We also provide data supporting that it is the CCL21 core domain together with CCL21-tail that determines the low potency of CCL21 in CCR7 induced G i mediated reduction in cAMP.
Chemotaxis is probably not governed via intracellular calcium signaling, whereas signaling via reduction of intracellular cAMP seems to be positively linked to migration as only the ligands that efficiently induce a decrease in cAMP seems to be able to induce migration with high potency (CCL19, CCL19 CCL21-tail , and CCL21 tailless ).
Our observations support a role for CCL19 that displays enhanced endocytosis and thus CCR7 cell surface down-regulation compared to CCL21, in short-lived processes, for example, the DC-T cell scanning process in the LNs (with CCL19 being secreted by activated DCs) and CCL21 being important for the initial LN homing from peripheral tissues. The in vivo generated truncated form of CCL21, CCL21 tailless that is produced via the action of DC released proteases and is mainly potent in inducing chemotaxis, is suspected to potentiate DC LN homing when many DCs are activated at the same time, during serious infections. 42 TA B L E 1 Summarizes potencies of the ligands used in the study. +++ indicates high, ++ medium, + low and (+) very low potency. NA is abbreviation for Not Assayed. In the current work, we focus on chemokine action in human DCs.
CCL19
There is reason to believe that chemokines may play different roles in different immune cell subtypes, thus CCL21 tailless (soluble CCL21) has been shown to be moderately more potent but much less efficient in inducing chemotaxis of primary human T-cells compared to CCL21, 19 a fact that may be related to low heparan sulphate proteoglycan cell surface expression on unstimulated (quiescent) T-cells. 43, 44 This is in contrast to human DCs, the chemotaxis of which is efficiently stimulated by CCL21 tailless , but less so by CCL21 14 , and that are known to express high levels of heparin sulphate, both in immature and mature states. 45 Based on this, it will be interesting to investigate the action of the chemokines guiding DC LN homing and scanning processes for their action in human naïve T cells.
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